These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 30980868

  • 1. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
    Xu Y, Xu H, Li M, Wu H, Guo Y, Chen J, Shan J, Chen X, Shen J, Ma Q, Liu J, Wang M, Zhao W, Hong J, Qi Y, Yao C, Zhang Q, Yang Z, Qian C, Li J.
    Cancer Lett; 2019 Jul 10; 454():78-89. PubMed ID: 30980868
    [Abstract] [Full Text] [Related]

  • 2. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 10; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 3. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS, Huang YH.
    J Exp Clin Cancer Res; 2019 Nov 26; 38(1):474. PubMed ID: 31771617
    [Abstract] [Full Text] [Related]

  • 4. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H, Xu H, Ma F, Zhan M, Yang X, Hua S, Li W, Li Y, Lu L.
    Cell Death Dis; 2020 Apr 08; 11(4):225. PubMed ID: 32269215
    [Abstract] [Full Text] [Related]

  • 5. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul 08; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 6. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y.
    Cell Death Dis; 2021 Jul 09; 12(7):691. PubMed ID: 34244479
    [Abstract] [Full Text] [Related]

  • 7. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
    Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, Yau TC, Poon RT, Pang RW.
    PLoS One; 2013 Jul 09; 8(11):e78675. PubMed ID: 24244338
    [Abstract] [Full Text] [Related]

  • 8. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L, Huang X, Chen J, Zhang K, Gu YH, Sun J, Cui SY.
    Mol Cancer Ther; 2020 May 09; 19(5):1197-1209. PubMed ID: 32220970
    [Abstract] [Full Text] [Related]

  • 9. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Liao LZ, Chen CT, Li NC, Lin LC, Huang BS, Chang YH, Chow LP.
    Int J Mol Sci; 2020 Dec 28; 22(1):. PubMed ID: 33379356
    [Abstract] [Full Text] [Related]

  • 10. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
    Qin CD, Ma DN, Zhang SZ, Zhang N, Ren ZG, Zhu XD, Jia QA, Chai ZT, Wang CH, Sun HC, Tang ZY.
    Cell Death Dis; 2018 May 01; 9(5):486. PubMed ID: 29706627
    [Abstract] [Full Text] [Related]

  • 11. IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.
    Xu QG, Yu J, Guo XG, Hou GJ, Yuan SX, Yang Y, Yang Y, Liu H, Pan ZY, Yang F, Gu FM, Zhou WP.
    Mol Oncol; 2018 Jun 01; 12(6):936-952. PubMed ID: 29689643
    [Abstract] [Full Text] [Related]

  • 12. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Jun 01; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 13. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B.
    Aging (Albany NY); 2020 Nov 16; 12(22):22975-23003. PubMed ID: 33203790
    [Abstract] [Full Text] [Related]

  • 14. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y, Sun M, Zhan X, Wu C, Geng P, Sun X, Wu Y, Zhang S, Qin J, Zhuang Z, Liu Y.
    J Exp Clin Cancer Res; 2019 Feb 15; 38(1):83. PubMed ID: 30770740
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y, Zhang Z.
    Biomed Pharmacother; 2017 Apr 08; 88():421-429. PubMed ID: 28122307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.